Resona Asset Management Co. Ltd. Makes New Investment in Pfizer Inc. (NYSE:PFE)

Resona Asset Management Co. Ltd. acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 1,845,310 shares of the biopharmaceutical company’s stock, valued at approximately $48,977,000.

A number of other institutional investors have also made changes to their positions in the company. Pioneer Trust Bank N A OR lifted its holdings in Pfizer by 30.4% in the 4th quarter. Pioneer Trust Bank N A OR now owns 12,560 shares of the biopharmaceutical company’s stock worth $333,000 after buying an additional 2,926 shares in the last quarter. Unison Advisors LLC lifted its stake in shares of Pfizer by 1.4% in the fourth quarter. Unison Advisors LLC now owns 88,978 shares of the biopharmaceutical company’s stock worth $2,361,000 after acquiring an additional 1,266 shares in the last quarter. Wescott Financial Advisory Group LLC boosted its holdings in Pfizer by 5.6% in the fourth quarter. Wescott Financial Advisory Group LLC now owns 16,381 shares of the biopharmaceutical company’s stock valued at $435,000 after purchasing an additional 864 shares during the last quarter. Foundry Partners LLC acquired a new stake in Pfizer during the 4th quarter valued at approximately $20,996,000. Finally, Huber Capital Management LLC increased its holdings in Pfizer by 142.4% during the 4th quarter. Huber Capital Management LLC now owns 488,288 shares of the biopharmaceutical company’s stock worth $12,954,000 after purchasing an additional 286,842 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. 0.06% of the stock is owned by company insiders.

Pfizer Stock Performance

Shares of PFE opened at $22.99 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 1 year low of $22.95 and a 1 year high of $31.54. The firm has a fifty day moving average of $25.87 and a 200-day moving average of $26.76. The company has a market cap of $130.39 billion, a price-to-earnings ratio of 16.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.10 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Bank of America reaffirmed a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.